{"id":64733,"date":"2025-10-07T09:16:07","date_gmt":"2025-10-07T09:16:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/64733\/"},"modified":"2025-10-07T09:16:07","modified_gmt":"2025-10-07T09:16:07","slug":"resalis-therapeutics-reports-durable-fat-selective-weight","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/64733\/","title":{"rendered":"Resalis Therapeutics Reports Durable, Fat-Selective Weight"},"content":{"rendered":"

Torino, Italy, October 7 \u2013 Resalis Therapeutics<\/a>, a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on its lead candidate RES-010, a first-in-class antisense oligonucleotide targeting microRNA-22 (miR-22). The data was presented at the European Association for the Study of Diabetes (EASD) in Vienna, Austria, the Obesity Science & Innovation Meeting in Boston, MA, and the Obesity Drug Development Summit Europe in Barcelona, Spain. The study evaluated RES-010 in a well-defined, non-human primate (NHP) model for obesity as both a monotherapy and in combination with the GLP-1 receptor agonist (GLP-1 RA) semaglutide, while also assessing weight control after treatment discontinuation.<\/p>\n

In this study, RES-010 demonstrated robust and durable weight reduction effects in obese NHPs maintained on a high-fat diet. After 10 weeks of treatment, RES-010 monotherapy achieved a 15% reduction in fat mass compared to semaglutide (16%), while also preserving lean mass (-1% with RES-010 versus -8% with semaglutide). In combination with semaglutide, RES-010 provided an additive benefit resulting in a 33% reduction of fat. Notably, after semaglutide interruption at week 10, the animals previously treated with the combination and still on RES-010 alone did not experience rebound weight gain despite a rapid increase in food intake. Four weeks after semaglutide discontinuation, animals that continued on RES-010 showed a further reduction of fat mass and a substantial recovery of lean mass. The stabilization of body weight observed with RES-010 treatment was sustained for at least 4 weeks in absence of any treatment. <\/p>\n

\u201cRES-010 delivers fat-selective weight loss, prevents rebound after GLP-1 RA discontinuation and shows durability beyond treatment, a truly unique feature in treating obesity,\u201d said Riccardo Panella, CSO of Resalis Therapeutics. \u201cBecause primates closely model human biology, these results strengthen our confidence in RES-010\u2019s profile as a first-in-class RNA therapy in obesity, with a clear differentiation from existing approaches. We are encouraged by these data and look forward to confirming its profile in our ongoing Phase 1 trial.\u201d <\/p>\n

\u201cThese results underscore RES-010\u2019s potential to reshape obesity treatment by offering benefits not achieved with existing approaches,\u201d said Alessandro Toniolo, CEO of Resalis Therapeutics. \u201cObesity is one of the fastest-growing health concerns worldwide, and there is a clear need for effective, durable, well-tolerated treatment options. We are excited to build on this momentum and are committed to our mission of transforming the standard of care in obesity.\u201d <\/p>\n

RES-010 is currently being evaluated in healthy lean and overweight to obese subjects. The ongoing Phase 1 trial (EUCT No.: 2024-514871-17-00<\/a>) is designed to assess the safety, tolerability, and pharmacokinetic profile of RES-010 in the described population, with preliminary data expected in mid-2026. <\/p>\n

About RES-010
RES-010 is designed to reprogram metabolic pathways, providing a potential disease-modifying therapeutic impact that could include high-quality, sustained weight loss. By specifically targeting miR-22, a master regulator of lipid biosynthesis, mitochondrial function, and adipose tissue transformation, RES-010 has the potential to go beyond conventional obesity treatments that focus solely on appetite reduction. This targeted approach has the potential to offer a more durable solution, addressing the complex biological underpinnings of obesity. The regulation of these pathways may result in a reduction of fat mass across various body parts, including visceral fat and hepatic stores. With its robust preclinical results, RES-010 has the potential to complement and enhance the efficacy of existing anti-obesity drugs, such as GLP-1 receptor agonists, and may extend their impact by providing a more comprehensive therapeutic solution.<\/p>\n

About Resalis Therapeutics<\/p>\n

Resalis Therapeutics is dedicated to developing RNA-based therapies that tackle the root causes of complex metabolic disorders. With its deep expertise in non-coding RNA and lipid metabolism, Resalis Therapeutics is advancing RES-010 as a safe, effective, and disease-modifying therapy, offering sustained weight loss and improved metabolic health. With strong preclinical data supporting its development, RES-010 is now in clinical trials, positioning Resalis Therapeutics as a key company in the evolving landscape of obesity treatment.<\/p>\n

For more information visit our website www.resalistherapeutics.com<\/a>.<\/p>\n

Contact:
Trophic Communications
Eva Mulder or Charlotte Spitz
+31 6 52 33 15 79
resalis@trophic.eu<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"Torino, Italy, October 7 \u2013 Resalis Therapeutics, a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on…\n","protected":false},"author":2,"featured_media":64734,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[4368,103,61,60,44241,44242,4369,44240,44239,44238,10421,2114],"class_list":["post-64733","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-glp-1","tag-health","tag-ie","tag-ireland","tag-mir-22","tag-nhp","tag-obesity","tag-res-010","tag-resalis","tag-resalis-therapeutics-srl","tag-semaglutide","tag-weight-loss"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/64733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=64733"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/64733\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/64734"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=64733"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=64733"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=64733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}